• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚太地区医疗器械制造、创新和营销的差距分析。

Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region.

机构信息

Department of Pharmaceutical Sciences, Nobel College, Affiliated to Pokhara University, Kathmandu, Nepal.

Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2022 Oct;22(7):1043-1050. doi: 10.1080/14737167.2022.2086122. Epub 2022 Jun 8.

DOI:10.1080/14737167.2022.2086122
PMID:35658768
Abstract

INTRODUCTION

Although similar in many aspects of manufacturing and regulatory provisions to medicines, medical devices have their provisions and attract considerable investments in manufacturing and innovation. While the U.S. holds the leading global position in the devices market, Asia Pacific (APAC) countries like China, Japan, Singapore, and South Korea have proved tremendous market potential holding top ten positions. Still, many APAC countries are import-reliant due to hurdles in technological innovation and regulatory provisions.

AREAS COVERED

The review aimed to explore those predictors or hurdles and analyzed these to enhance the region's export capacity gradually.

EXPERT OPINION

Policymakers in APAC countries with no device manufacturing and health technology assessment capacities would be benefited from the review. The findings showed the presence of a gap in manufacturing, innovation, and marketing of devices within the APAC region and between APAC and western countries. Stringent regulatory measures and quality indicators are still lacking in many APAC nations, and there is an urgent need to harmonize regulatory standards. Being a region constituting over one-third of the global population, a considerable investment in innovation, manufacturing, and establishing quality standards is urgently needed among APAC countries to ensure an adequate supply of quality medical devices.

摘要

简介

医疗器械在制造和监管规定方面与药品有许多相似之处,但也有其自身的规定,并吸引了大量资金投入到制造和创新中。虽然美国在医疗器械市场占据领先地位,但中国、日本、新加坡和韩国等亚太(APAC)国家也证明了其巨大的市场潜力,位居前十。尽管如此,由于技术创新和监管规定方面的障碍,许多亚太国家仍然依赖进口。

涵盖领域

本次综述旨在探讨这些预测因素或障碍,并对其进行分析,以逐步提高该地区的出口能力。

专家意见

没有医疗器械制造和卫生技术评估能力的亚太国家的政策制定者将从本次综述中受益。研究结果表明,亚太地区内部以及亚太地区与西方国家之间在医疗器械的制造、创新和营销方面存在差距。许多亚太国家仍然缺乏严格的监管措施和质量指标,迫切需要协调监管标准。作为占全球人口三分之一以上的地区,亚太国家迫切需要在创新、制造和建立质量标准方面进行大量投资,以确保高质量医疗器械的充足供应。

相似文献

1
Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region.亚太地区医疗器械制造、创新和营销的差距分析。
Expert Rev Pharmacoecon Outcomes Res. 2022 Oct;22(7):1043-1050. doi: 10.1080/14737167.2022.2086122. Epub 2022 Jun 8.
2
Pharma Opportunities and Risks Multiply as Regulatory Reform Remakes APAC: Expanded Accelerated Pathways Challenge Developer Value Story, Evidence Collection, and Market Access Strategies.随着监管改革重塑亚太地区,制药机遇与风险倍增:加速通道的扩展对开发者的价值主张、证据收集及市场准入策略构成挑战。
Ther Innov Regul Sci. 2018 Jul;52(4):514-522. doi: 10.1177/2168479018769296. Epub 2018 Apr 19.
3
Asia Partnership Conference of Pharmaceutical Associations (APAC) Report on Regulatory Agility Implemented During the COVID-19 Pandemic: Inspiring Partnerships and Recommendations for the Way Forward.亚洲制药协会伙伴关系会议(APAC)在 COVID-19 大流行期间实施监管敏捷性的报告:激发伙伴关系的建议和前进道路。
Ther Innov Regul Sci. 2023 Jan;57(1):12-25. doi: 10.1007/s43441-022-00435-8. Epub 2022 Sep 29.
4
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR).在亚太地区建立多发性骨髓瘤临床登记处:亚太骨髓瘤和相关疾病登记处(APAC MRDR)。
BMC Med Res Methodol. 2024 May 2;24(1):102. doi: 10.1186/s12874-024-02227-0.
5
Strengthening Health Products Regulatory Systems to Enhance Access to Quality Health Products in the Asia-Pacific.加强卫生产品监管体系以增加亚太地区优质卫生产品的可及性。
Ther Innov Regul Sci. 2018 Nov;52(6):751-754. doi: 10.1177/2168479018769285. Epub 2018 Apr 12.
6
Variability in research culture across busy catheterisation labs in the Asia-Pacific region.亚太地区繁忙的导管插入实验室之间研究文化的差异。
AsiaIntervention. 2024 Feb 29;10(1):26-33. doi: 10.4244/AIJ-D-23-00005. eCollection 2024 Feb.
7
Regulatory reliance for convergence and harmonisation in the medical device space in Asia-Pacific.亚太地区医疗器械领域趋同与协调的监管依赖
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-009798.
8
Expert commentary on the challenges and opportunities for surgical site infection prevention through implementation of evidence-based guidelines in the Asia-Pacific Region.专家评论:通过在亚太地区实施基于证据的指南,预防手术部位感染的挑战与机遇。
Antimicrob Resist Infect Control. 2021 Apr 1;10(1):65. doi: 10.1186/s13756-021-00916-9.
9
Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023.亚太地区晚期前列腺癌的管理:2023 年亚太前列腺癌共识会议总结。
Asia Pac J Clin Oncol. 2024 Aug;20(4):481-490. doi: 10.1111/ajco.14064. Epub 2024 Apr 16.
10
A study of medical device regulation management model in Asia.亚洲医疗器械监管管理模式研究
Expert Rev Med Devices. 2016 Jun;13(6):533-43. doi: 10.1080/17434440.2016.1184970.

引用本文的文献

1
Does the trade of medical products contribute to promoting human development?-An empirical analysis based on data from China and RCEP countries.医疗产品贸易是否有助于促进人类发展?——基于中国与《区域全面经济伙伴关系协定》(RCEP)国家数据的实证分析
Front Public Health. 2025 Aug 13;13:1650225. doi: 10.3389/fpubh.2025.1650225. eCollection 2025.
2
Evaluation of Medical Device Aging and Replacement Decisions within Hospital Environments: A User-Centered Approach.医院环境中医疗设备老化与更换决策的评估:一种以用户为中心的方法。
Risk Manag Healthc Policy. 2025 Jul 1;18:2201-2215. doi: 10.2147/RMHP.S478245. eCollection 2025.
3
Health technology assessment for digital health Technologies in India: a framework for action.
印度数字健康技术的卫生技术评估:行动框架
Int J Technol Assess Health Care. 2024 Nov 4;40(1):e70. doi: 10.1017/S0266462324000345.
4
A review on the evolving environment of medical device real-world evidence regulation on market access in the USA.美国医疗器械真实世界证据监管在市场准入方面的不断演变环境综述。
Cost Eff Resour Alloc. 2024 Oct 25;22(1):75. doi: 10.1186/s12962-024-00582-9.
5
Unveiling, Analyzing the Mechanisms of, and Proposing Solutions for Bribery in Japan's Medical Device Sector.揭示、剖析日本医疗器械行业贿赂行为的机制并提出解决方案
Cureus. 2024 May 29;16(5):e61285. doi: 10.7759/cureus.61285. eCollection 2024 May.
6
The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis.射血分数保留的心力衰竭(HFpEF)中冠状动脉微血管功能障碍(CMD)的患病率:一项系统评价和荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):405-416. doi: 10.1007/s10741-023-10362-x. Epub 2023 Oct 23.
7
Analyzing the Effectiveness of Data-Linked Projects for Health Promotion in Public Health Centers of South Korea.分析韩国公共卫生中心数据关联项目对健康促进的有效性。
Risk Manag Healthc Policy. 2023 Jun 16;16:1101-1117. doi: 10.2147/RMHP.S413630. eCollection 2023.
8
Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II.社论:健康经济数据在新医疗技术政策制定与报销中的作用,第二卷。
Front Public Health. 2023 Mar 27;11:1179300. doi: 10.3389/fpubh.2023.1179300. eCollection 2023.
9
Editorial: Global excellence in health economics: Asia and Australasia.社论:全球卫生经济学卓越成就:亚洲和澳大拉西亚
Front Public Health. 2023 Mar 24;11:1172632. doi: 10.3389/fpubh.2023.1172632. eCollection 2023.
10
Editorial: Asian health sector growth in the next decade-Optimism despite challenges ahead.社论:未来十年亚洲卫生部门的增长——尽管前路有挑战,但仍保持乐观。
Front Public Health. 2023 Feb 20;11:1150917. doi: 10.3389/fpubh.2023.1150917. eCollection 2023.